TEM (Tempus) Operating Margin

Symbol and logo of brand Tempus AI, Inc (TEM)

Partnerships with oncology centers and pharmaceutical behemoths to develop AI-driven drugs drive the dynamics of operating margins shown on the GURU.Markets time chart for Tempus AI, Inc (TEM), where the indicator stands at -17.50. Strategic growth is based on the scalable aggregation of genetic data for the sale of analytics, while business resilience is guaranteed by integrated biomaterial collection logistics and diversified supply channels for laboratory resources.

tempus.com (TEM): Operating Sales Margin from 06/15/2024 to 11/19/2026

Analytical breakdowns for Tempus Labs (TEM)

- stock quotes and analyst forecast:
- business market valuation indicators:
Basic company analysis:tempus.com
Core merchandise of Tempus AI Inc

Operating margin measures the share of profit from core business processes relative to total revenue, allowing for an assessment of cost management efficiency before accounting for debt obligations and taxes. By analyzing operating margin trends, an investor determines the financial stability of Tempus AI, Inc (TEM), where the monetization of clinical data sets through contracts with pharma behemoths should translate into increased profitability for this high-tech business.

Direct competitors

QGEN (Qiagen NV) - Operating Margin|Operating Sales Margin Ionis Pharma (IONS)|Operating Profitability Repligen Corp (RGEN)|RNA - Operating Return on Sales|crisprtx.com - Operating Sales Margin|Operating Profit Rate WGS|RARE - Operating Profitability|Beam Tx (BEAM) - Operating Sales Margin|SRPT (Sarepta Therapeutics Inc) - Operating Sales Margin|TWST: Operating Profit Ratio|TXG (10xgenomics.com) - Operating Margin|NTLA (Intellia Therapeutics, Inc.) - Operating Profit Ratio|Operating Profitability Stoke Corp (STOK)|Profitability of Operations BioLife|Operating Margin WVE (Wave Life Sciences Ltd)|MAZE: Return on Sales by Operating Profit|Sionna Therapeutics, Inc. - Operating Margin|Operating Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Operating Sales Margin|QURE - Profitability of Operations|MGTX (MeiraGTx Corp) - Operating Margin|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability